Chong Kun Dang and Dong-A ST Plan to Launch Nesp biosimilar in Japan

 Chong Kun Dang and Dong-A ST Plan to Launch Nesp biosimilar in Japan

Chong Kun Dang and Dong-A ST Plan to Launch Nesp biosimilars in Japan

Shots:

  • The companies filed for their Nesp biosimilar in Oct’2018 with its awaited launch in H2’19
  • The original drug was developed in collaboration with US’ Amgen and Japan’s Kyowa Hakko while the patent expired in the US AND Korea in 2015 and 2024. The worldwide sales for Nesp is expected to be $3B 
  • Nesp (darbepoetin alfa) is an erythropoietin drug and is a catalyst for red blood cell production involved in treating anemia from chronic renal failure or anticancer treatments

Click here to read full press release/ article | Ref: Korean Hearld | Image: Twitter  

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post